Organigram Global (NASDAQ:OGI) Posts Quarterly Earnings Results, Meets Estimates

by · The Cerbat Gem

Organigram Global (NASDAQ:OGI – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports. Organigram Global had a net margin of 6.03% and a negative return on equity of 15.41%.

Here are the key takeaways from Organigram Global’s conference call:

  • OrganiGram reported a challenging Q2, with net revenue of CAD 59.8 million, down about 9% year over year, as execution issues in vapes and infused pre-rolls weighed on results.
  • Adjusted gross margin fell to 31% and adjusted EBITDA dropped to CAD 0.9 million, reflecting weaker mix, higher returns, and lower recreational revenue. Net loss also included a CAD 5.8 million impairment tied to the company’s U.S. hemp-derived products business.
  • Management said the main operational problems in pre-rolls and vapes have been identified and remediated, and they are already seeing improving quality and competitiveness. They expect recovery to continue in Q3 and Q4, alongside seasonal tailwinds.
  • The company emphasized strong underlying performance in other categories, including flower share gains, continued strength in edibles, beverages, and concentrates, and a record quarterly harvest of over 32,000 kilograms. OrganiGram also said its cultivation yields and genetics work are lowering costs and improving efficiency.
  • Management expects the Sanity Group acquisition to drive a meaningful step-up in the second half of fiscal 2026, supporting international growth, especially in Germany and other European markets. Reflecting this, OrganiGram raised guidance to net revenue above CAD 350 million, with adjusted EBITDA and adjusted gross margin above FY2025 levels and free cash flow near breakeven.

Organigram Global Price Performance

Shares of NASDAQ OGI traded down $0.19 during trading on Tuesday, reaching $1.13. 2,082,135 shares of the stock traded hands, compared to its average volume of 746,364. Organigram Global has a 52-week low of $1.10 and a 52-week high of $2.24. The stock has a market capitalization of $158.37 million, a P/E ratio of 8.04 and a beta of 1.50. The company has a 50-day moving average of $1.41 and a 200-day moving average of $1.54.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Canaccord Genuity Group assumed coverage on Organigram Global in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. ATB Cormark Capital Markets downgraded Organigram Global from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Finally, Wall Street Zen lowered shares of Organigram Global from a “hold” rating to a “sell” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Read Our Latest Stock Analysis on OGI

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OGI. Walleye Capital LLC bought a new stake in shares of Organigram Global in the fourth quarter worth about $25,000. StoneX Group Inc. bought a new stake in Organigram Global during the fourth quarter worth about $30,000. HRT Financial LP bought a new stake in Organigram Global in the 4th quarter worth approximately $52,000. Bank of America Corp DE lifted its holdings in shares of Organigram Global by 1,678.1% during the 3rd quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock valued at $76,000 after buying an additional 35,256 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Organigram Global in the fourth quarter worth $188,000. 34.63% of the stock is owned by hedge funds and other institutional investors.

About Organigram Global

(Get Free Report)

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.

Featured Articles